Bupropion Sr/ Er Tablets Suppliers & Bulk Manufacturers
Available Forms: Sustained-Release (SR) Tablets, Extended-Release (XL) Tablets
Available Strengths: 100 mg, 150 mg, 200 mg (SR); 150 mg, 300 mg (XL)
Reference Brands: Wellbutrin® SR/XL(US); Zyban®(EU & US)
Category:
Psychiatry / Mental Health
Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that enhances neurotransmitter activity without significantly affecting serotonin. Available in SR and ER forms, it is used to treat major depressive disorder (MDD), seasonal affective disorder (SAD), and to aid smoking cessation, with a lower risk of sexual side effects and weight gain.
Bupropion SR/ ER Tablets is available in Sustained-Release (SR) Tablets, Extended-Release (XL) Tablets
and strengths such as 100 mg, 150 mg, 200 mg (SR); 150 mg, 300 mg (XL).
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Bupropion SR/ ER Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Bupropion SR/ ER Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Bupropion sustained-release (SR) and extended-release (ER) tablets are FDA-approved in the United States for the treatment of major depressive disorder (MDD) and seasonal affective disorder (SAD), and as an aid in smoking cessation under brand variations. U.S. regulations require Boxed Warnings regarding suicidal thoughts in young adults, seizure risk, and contraindications. Manufacturers must ensure GMP compliance, bioequivalence data, and post-marketing safety reporting. In the European Union, bupropion is authorized under national and centralized procedures for depression and smoking cessation. EU approval mandates a Risk Management Plan (RMP), Periodic Safety Update Reports (PSURs), and pharmacovigilance systems. For dossier-ready supply, visit Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing